AI Collaborations, From Strategic License to Strategic Acquisition

Artificial intelligence continues to reshape healthcare delivery in diagnostics, imaging, and care coordination. Established platforms often pursue phased relationships that begin with commercial alignment and include potential for full integration. This approach raises questions for transactions counsel on structuring collaborations to accelerate deployment while preserving optionality. Initial alignment frequently takes the form of an exclusive or field-limited license with a minority equity investment. This enables access to technology, influence on development, and clinical evaluation while mitigating integration and regulatory risk. Exclusivity definitions cover specialty, site of care, modality, patient population, geography, or combinations, often with performance milestones. Clear delineation of background intellectual property, derivative works, algorithm improvements, and data usage rights is essential. Parties distinguish ownership of model weights, fine-tuned models, embeddings, and outputs. Exclusivity on foundation model wrappers protects configuration and fine-tuning but not underlying models from providers such as Meta, Google, OpenAI, or Anthropic. Ownership of AI-generated output remains legally unsettled. Organizations treat prompts and fine-tuning as trade secrets requiring confidentiality controls. Training data diligence addresses third-party infringement claims. A minority equity investment aligns incentives with governance rights such as board observation and information rights. Structural mechanisms including rights of first refusal or call options preserve acquisition paths. The initial phase functions as live diligence on performance and scalability to inform future integration.